INTRODUCTION
============

Obesity and diabetes are a worldwide public health issue with extensive medical, social, and economic consequences ([@B89]; [@B65]). Obesity (body mass index ≥30 kg of body weight/m^2^ of height) has negative effects on health and increases the risk of developing a variety of diseases, including cardiovascular syndromes, some cancers, and diabetes mellitus ([@B60]; [@B14]; [@B7]; [@B16]). Over the past three decades, the prevalence of obesity has doubled in the USA and in Europe ([@B62]; [@B82]). Although according to the most recent data published in the 2005--2006 update of the National Health and Nutrition Examination Survey (NHANES) obesity rates have stabilized, others ([@B85]) expect that the obesity "epidemic" will only continue to worsen, with as many as 75% of Americans and of Europeans potentially being overweight in the year 2020. Physicians will undoubtedly encounter obese people in clinical practice and must, then, be able to identify and address care needs specific to this patient population.

This minireview focuses on relationship between the autonomic nervous system and orexin-A in the control of eating behavior, energy expenditure, and body weight regulation. The "thermoregulatory hypothesis" of food intake ([@B23]) is analyzed, underlining the role played by orexin-A in the control of eating behavior related to body temperature.

ENERGY HOMEOSTASIS
==================

Energy homeostasis is determined by the balance between intake of calories and energy expenditure. This is regulated by interconnected neuroendocrine and autonomic pathways ([@B48]).

Resting energy expenditure (REE) accounts for 60--75% of total daily energy expenditure. Several factors contribute to the inter-individual variability in REE such as fat-free mass (FFM; [@B87]), sympathetic nervous system (SNS) activity ([@B86]; [@B41]), and endocrine status \[e.g., thyroid hormone ([@B9])\]. REE decreases with age ([@B64]). This decline is due not only to the loss of FFM and an alteration in its metabolically active components, but also to the reduction in physical activity.

HYPOTHALAMUS AND OREXINS
========================

The hypothalamus, a key component for regulation of energy homeostasis, continuously monitors signals that reflect energy status and initiates appropriate behavioral and metabolic responses ([@B74]). It controls glucose utilization in insulin-sensitive organs, such as skeletal muscle, as well as whole-body energy metabolism ([@B73]; [@B20]).

Orexins A and B are hypothalamic neuropeptides, involved in the regulation of feeding behavior, sleep-wakefulness rhythm, and neuroendocrine homeostasis ([@B33]; [@B55]; [@B84]), as reported in **Figure [1](#F1){ref-type="fig"}**.
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These peptides derive from the prepro-orexin (preprohypocretin) gene, which encodes a precursor (130 amino acids in rodents, 131 residues in humans) that is cleaved into orexin-A (synonymous with hypocretin-1; 33 amino acids) and orexin-B (hypocretin-2; 28 residues; [@B66]). Orexins promote both arousal and feeding ([@B75]). Orexin-A binds to two G-protein-coupled receptors, orexin receptor-1 (hypocretin receptor-1) and orexin receptor-2 (hypocretin receptor-2). The expression pattern of mRNA encoding two orexin receptors (OX1R andOX2R) in the rat's brain has been demonstrated ([@B79]; [@B38]). Within the hypothalamus, expression for the OX1R mRNA was largely restricted in the ventromedial (VMH) and dorsomedial hypothalamic nuclei, while paraventricular nucleus, VMH, and arcuate nucleus contain high levels of OX2R mRNA, as well as in mammillary nuclei ([@B91]). [@B37] have demonstrated that levels of OX1R mRNA significantly increased in the VMH of rats after 20 h of fasting. An initial decrease (14 h) and a subsequent increase (20 h) in OX1R mRNA levels after fasting were observed in the dorsomedial hypothalamic nucleus. Levels of OX2R mRNA increased in the arcuate nucleus, but they didn't change in the dorsomedial hypothalamic nucleus and paraventricular hypothalamic nucleus following fasting ([@B37]).

Orexin neurons may also functionally interact with glucose-sensitive neurons in the hypothalamus, notably the glucose-responsive cells (glucose-excited neurons: stimulated by rising glucose levels) found predominantly in the VMH, and the glucose-sensitive neurons (glucose-inhibited neurons: stimulated when glucose falls) that constitute 30% of lateral hypothalamic area (LHA) neurons. There are synaptic contacts between orexin neurons and glucose-sensitive cells in the LHA ([@B69]), while orexin-A specifically stimulates the glucose-sensitive cells ([@B36]). On the contrary, orexin-A inhibits glucose-responsive neurons in the VMH ([@B69]). [@B59] suggest that some glucose-sensitive neurons express orexins. In the medulla, orexin neurons innervate not only the ventral area ([@B92]), but also the nucleus of the solitary tract ([@B8]), which is an important relay station that receives sensory signals, such as portal vein glucose availability and gastric distension from the viscera. These signals are conveyed to the hypothalamus ([@B25]).

Sugar-sensing neurons exist in restricted brain regions, such as hypothalamus and brain stem, and they are classified into two groups, called glucose-excited (GE) neurons and glucose-inhibited (GI) neurons, in terms of the mode of response to extracellular glucose changes within physiological cerebrospinal fluid (CSF) range ([@B5]; [@B18]). For instance, orexin neurons in the LHA and neuropeptide Y (NPY)/agouti-related peptide (AgRP) neurons in the ARC are glucose-inhibited, whereas melanin-concentrating hormone (MCH) neurons in LHA and proopiomelanocortin (POMC) neurons in the ARC are glucose-excited ([@B6]; [@B5]). The sugar sensing of orexin neurons, which is a major class of GI neurons, is metabolism-independent, since the glucose response is unaffected by glucokinase inhibitors, and mimicked by a non-metabolizable glucose analog 2-deoxyglucose ([@B17]), although the accurate mechanisms, particularly the functional molecules relevant to glucose-induced inhibition, have not yet been explained. Orexin neurons are not inhibited by [L]{.smallcaps}-glucose, galactose, α-methyl-[D]{.smallcaps}-glucoside, or fructose, whereas GE neurons can sense galactose. More recently, it has been suggested that orexin neurons function as a "conditional glucosensor," because the electrical activity of orexin neurons is more potently inhibited by glucose when intracellular energy levels (i.e., cytosolic levels of pyruvate, lactate, or ATP) are low, whereas high energy levels attenuate the glucose response in orexin neurons ([@B83]). Besides, [@B90] have reported that a continuous intracerebroventricula (ICV) infusion of orexin-A (1 mmol/L, 5 μL/h) into rats fasted for 5 h brought about an increase in plasma glucose levels, and prevented a daytime decrease of endogenous hepatic glucose production (EGP). Hepatic sympathetic, but not parasympathetic, denervation blocked the orexin induced apparent enhancement of EGP.

In addition, when the γ-aminobutyric acid receptor antagonist bicuculline was administered in the perifornical area in order to activate orexin neurons, basal EGP was increased, and insulin-mediated suppression of EGP was attenuated, but the insulin-induced glucose disposal was enhanced ([@B90]).

In addition, the presence of orexin receptors in other cerebral areas suggests that orexin-A plays additional functions ([@B33]). It has been demonstrated that the orexins play a role in sleep regulation ([@B3]). Deficiency in orexin neurotransmission results in the sleep disorder narcolepsy in mice, dogs, and humans ([@B53]). Orexin derangements in patients with narcolepsy were associated with an increased body mass index ([@B67]) and a higher risk of type-II diabetes mellitus ([@B24]).

Orexins exert peripheral effect and this was suggested by the detection of substantial levels of orexins in plasma ([@B1]), as well as the presence of orexin receptors in several peripheral tissues, including the gastrointestinal tract (GIT), endocrine pancreas, adrenal glands, and adipose tissue ([@B12]; [@B21]).

[@B71] have demonstrated that plasma orexin levels are one-fifth to one-eighth of orexin CSF values. However, the source of orexin in peripheral tissue is still unclear. Is orexin directly released into the blood stream or leaked from the CSF? One possibility is that orexin is released from the brain. The other possibility is that orexin is produced directly in peripheral tissues. Orexin-immunoreactive cells are observed in the gastrointestinal tract and pancreas. However, the question of orexin synthesis in peripheral tissue is still under discussion. Further studies are needed to better understand orexin physiology in peripheral tissues.

The influence of orexin-A on metabolic status and plasma glucose level may contribute to increase diabetics morbidity and mortality ([@B42]). It has been proved that orexins affect the plasma lipoprotein profile and insulin glucose homeostasis ([@B59]). Orexins stimulate insulin release from pancreatic cells *in vivo* and *in vitro* ([@B61]). Several studies have focused on finding out the relationship between circulating orexin and fat mass and have proved that there is a strong correlation between low plasma orexin and obesity ([@B1]; [@B39]). A significant issue is whether this naturally occurring biological peptide "orexin" in useful in weight management or obesity treatment. Many suggest that when orexin is peripherally injected, it activates thermogenesis, without limiting feeding or increasing physical activity. These encouraging observations have paved the way for clinical testing of the thermogenic potential of orexin ([@B40]).

Orexin-A controls glucose production and utilization in the peripheral tissues via the autonomic nervous system ([@B80]). These conclusions demonstrate that orexin is involved in the control of central and peripheral hormonal actions for the maintenance of glucose homeostasis, though it has been demonstrated that glucose control remains following decerebration ([@B13]). Existing evidence suggests that orexins induce glucose production in the liver ([@B72]) and help glucose uptake in skeletal muscle ([@B90]). In addition it has been shown that orexins A and B differentially regulate glucagon release from pancreas ([@B2]).

In summary, there is substantial evidence in the literature that helps to define the physiological role of orexin neurons, and their connections, as reported in **Figure [2](#F2){ref-type="fig"}**. For instance, anatomical works by [@B32] and [@B31]; physiological studies by [@B28] and [@B27] in glucose-regulation, and [@B56] in thermoregulation. More recently, opto- and pharmaco-genetic tools also have been used to investigate the physiological role of these neurons ([@B22]; [@B26]). Finally, hypothalamic orexin neurons co-express glutamate vesicular transporters ([@B63]), suggesting an important role of this neurotransmitter in the orexinergic pathway.
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THE SYMPATHETIC NERVOUS SYSTEM
==============================

Eating is a complex behavior that partly involves the sympathetic nervous system. This sympathetic involvement is exerted by an influence on body temperature, in agreement with the "thermoregulatory hypothesis" of eating behavior ([@B23]). Obviously, the role of the sympathetic system in controlling the eating behavior is not restricted only to changes in body temperature. For instance, the aforementioned glucose-control involves the sympathetic system.

Orexin-A also influences body temperature. In fact, an ICV administration of orexin-A induces an increase in firing rate of the sympathetic nerves to BAT, accompanied with a rise in BAT and colonic temperatures ([@B52]). The simultaneous increase in heart rate and body temperature after an ICV injection of orexin-A shows a generalized activation of the sympathetic nervous system. Few studies have been made on the topic of the roles played by different cerebral areas involved in the induction of the above-mentioned tachycardia and hyperthermia ([@B44], [@B45], [@B50]).

The sympathetic adjustment of thermoregulation also implies in energy expenditure. The functional organization and neurochemical influences within the CNS networks governs the level of BAT sympathetic nerve activity to produce the thermoregulatory and metabolically driven alterations in BAT thermogenesis and energy expenditure that contribute to overall energy homeostasis ([@B58]). BAT thermogenesis contributes to the maintenance of body temperature during cold exposure and to the elevated core temperature during several behavioral states, including wakefulness, the acute phase response (fever), and stress. BAT energy expenditure requires metabolic fuel availability and contributes to energy balance.

The consequences of the "thermoregulatory hypothesis" of eating behavior are that subjects with a high set-point of body temperature and/or low sympathetic activity are induced to eat a high quantity of food to elevate the sympathetic discharge and body temperature. Many studies ([@B30]; [@B57]) indicate that some forms of obesity can be regarded as instances of regulation at an elevated set point, while other forms seemingly result from a regulatory dysfunction, as already reported by [@B29].

Conversely, subjects with a low thermal set-point and/or a high sympathetic tone need to introduce a lower quantity of food to reach a prefixed thermal set-point. Alterations of postprandial thermogenesis due to a reduced response of sympathetic activation can play an important role in inducing obesity. In other words, subjects with a low postprandial sympathetic activation need to introduce a higher quantity of foot to reach a prefixed body temperature. On the other hand, being overweight increases the sympathetic discharge that contributes to induce diseases related to abnormal body weight ([@B34]).

Chronic sympathetic over activity is also known to be present in central obesity, and many evidences demonstrate the consequence of a high sympathetic outflow to organs such as the heart, kidneys, and blood vessels. Chronic sympathetic nervous system over activity can also contribute to a further decline of insulin sensitivity, creating a vicious cycle that may lead to the development of the metabolic syndrome and hypertension. The cause of this over activity is not clear, but may be driven by certain adipokines ([@B70]). In addition, the postprandial activation of the peripheral sympathetic nervous system is fundamental to maintain energy balance. A contribution of postprandial sympathetic activation to the thermic effect of food is not always evident and depends on the size and composition of the meal, with carbohydrates having the clearest effect. Signals related to food intake from various origins (e.g., gut, hepatoportal area, chemoreceptors) are integrated in the brain and result in increased peripheral sympathetic outflow. It is of interest to emphasize the role of diet composition (according to the life style of subjects) in the level of sympathetic activation during the day in view of the potential role of adrenergic over activity in the pathogenesis of obesity and its metabolic syndrome ([@B81]).

Power spectral analysis (PSA) of the heart rate variability (HRV) is considered a non-invasive method for quantitative and qualitative evaluation of the autonomic nervous system activity in various fields of research and clinical studies. In the frequency domain method of HRV, the high frequency (HF) component is associated solely with parasympathetic activity. The low frequency (LF) component is associated with both sympathetic and parasympathetic activities, but sympathetic activity is the greater contributor. LF power may correlate more with baroreflex function and/or stress that with the cardiac sympathetic innervations ([@B43]; [@B68]).

This approach should modify the interpretations about the sympathetic function in the pathophysiology of the obesity. In a study conducted in our laboratory ([@B46]), we demonstrated that LF and HF values of premenopausal obese women were lower than values of lean women. In postmenopause, LF and HF have a comparable decline in lean and obese women, as a consequence no difference can be found. These results suggest a reduction of the vegetative modulation in obese young women and the reduction of the autonomic control regards both the sympathetic and parasympathetic components ([@B47]). The reduction of the sympathetic branch could be an important factor in the maintenance of obesity in premenopausal age. Indeed, a reduction in the sympathetic activity could be linked to a low energy expenditure, so that a reduced energetic cost could explain the higher body weight in premenopausal women. In this experiment, the autonomic activity of postmenopausal women is lower than that of premenopausal subjects, though a better indicator of the sympathetic activity would be very low frequencies ([@B15]). This indicates that the modifications of the autonomic modulation cannot be included among factors related to obesity in postmenopausal subjects. Many experimental evidences have demonstrated that an increase in sympathetic and thermogenic activity reduces food intake. Therefore, the obesity can be due to an increase in food intake associated to a reduced activity of the sympathetic nervous system. On the other hand, a study revealed lower respiratory sinus arrhythmia, as evaluated by the HF-HRV spectral analysis combined with deep breathing tests, which points to the presence of cardiac vagal dysfunction in obese adolescents ([@B78]). Importantly, autonomic imbalance with decreased parasympathetic activity maybe the final common pathway in numerous conditions associated with increased morbidity and mortality ([@B77]). The evaluation of cardio respiratory interactions, in particular the heart rate variability, can provide diagnostic information about early subclinical autonomic dysfunction in obesity. Traditionally, there have been two hypotheses about the nature of the predominate abnormality in SNS behavior in human obesity. [@B4] used the acronym "MONA LISA" to describe his hypothesis that Most Obesities kNown Are Low In Sympathetic Activity. This vision was based principally on studies in rodents that exhibited low SNS activity and morbid obesity following lesions in the ventromedial hypothalamus. As such, low SNS activity was considered causal in the development of obesity. In contrast, [@B35] viewed SNS activation targeting the heart, blood vessels and kidneys as a critical relation to the well documented relation between obesity and hypertension ([@B19]; [@B10]).

PARADOXICAL EATING BEHAVIOR: HYPERPHAGIA AND HYPOPHAGIA BY OREXIN-A
===================================================================

Since orexin-A is able to induce both the activation of thermogenesis and hyperphagia, [@B51] tested the possibility that a previous thermogenic activation induced by orexin-A can modify eating behavior. Food intake and body temperature were monitored in 24 h-fasting male Sprague-Dawley rats for 15 h after food presentation during the dark period. Orexin-A was injected into the lateral cerebral ventricle 6 h before food presentation. Food intake and body temperature were controlled also in rats receiving orexin-A at the same time of food presentation. Orexin-A caused the same elevation of body temperature in both groups, while food intake was significantly lower in the group receiving orexin-A 6 h before food presentation in comparison to the other group. This study demonstrated that the effects on food intake induced by orexin-A depend on the time of food presentation. This suggest to revise the role of orexin-A in the control of food intake. The name assigned to this peptide was due to the strong increase in food intake after an orexin-A administration, assigning a fundamental role in the induction of food intake ([@B88]; [@B69]). The results of the above publication call for a re-discussion of this role, underlining the importance of orexin-A in the control of the sympathetic activity and body temperature, which in turn affects food intake. An ICV injection of orexin-A induces an increase in the sympathetic activity and in the body temperature independently of food ingestion, that is reduced in the rats with a delayed presentation of food. This suggests that the effects on body temperature are prevalent with respect to eating behavior. Then, orexin-A can induce hyperphagia, but also hypophagia, contradicting the significance of this name that assign a primary hyperphagic effect to this peptide. For this reason, orexin-A cannot be considered a substance with a primary hyperphagic effect.

Orexin-A can induce hypophagia or hyperphagia ([@B69]), but it always induces an activation of thermogenesis ([@B54], [@B49]). We believe that this peptide elevates the thermoregulatory set-point, inducing the reactions to reach the new level of body temperature. The increase in food intake, obtained in the rats with a non-delayed presentation of food, could be a reaction aimed to reach an elevated body temperature. Indeed, food ingestion induces a rise in body temperature due to postprandial thermogenesis ([@B11]; [@B76]; [@B48]; [@B41], [@B39]). The hyperphagic effect of orexin-A disappears when the body temperature is already increased, so that a reduction in food intake can happen in this condition.

Although selective activation of orexin neurons directly can elicit eating behavior ([@B26]), the above-reported demonstrations support the idea that orexin-A controls body temperature and subsequently eating behavior.
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